Selected article for: "comparator cohort and large scale"
Author: Nishimura, Akihiko; Xie, Junqing; Kostka, Kristin; Duarte-Salles, Talita; Bertolín, Sergio Fernández; Aragón, María; Blacketer, Clair; Shoaibi, Azza; DuVall, Scott L; Lynch, Kristine; Matheny, Michael E; Falconer, Thomas; Morales, Daniel R; Conover, Mitchell M; You, Seng Chan; Pratt, Nicole; Weaver, James; Sena, Anthony G; Schuemie, Martijn J; Reps, Jenna; Reich, Christian; Rijnbeek, Peter R; Ryan, Patrick B; Hripcsak, George; Prieto-Alhambra, Daniel; Suchard, Marc A
Title: Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
  • Cord-id: 4rs3ha1u
  • Document date: 2021_3_24
    • ID: 4rs3ha1u
    Snippet: Alpha-1 blockers, often used to treat benign prostate hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storms release. We conducted a prevalent-user active-comparator cohort study to assess association between alpha-1 blocker use and risks of three COVID-19 outcomes: diagnosis, hospitalization, and hospitalization requiring intensive services. Our study included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH therapy during
    Document: Alpha-1 blockers, often used to treat benign prostate hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storms release. We conducted a prevalent-user active-comparator cohort study to assess association between alpha-1 blocker use and risks of three COVID-19 outcomes: diagnosis, hospitalization, and hospitalization requiring intensive services. Our study included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH therapy during the period between November 2019 and January 2020, found in electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including large-scale propensity score matching/stratification and negative control calibration. We found no differential risk for any of COVID-19 outcome, pointing to the need for further research on potential COVID-19 therapies.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute pneumonia: 1, 2, 3, 4, 5, 6, 7
    • absence presence and acute pneumonia respiratory distress: 1, 2
    • absence presence and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • accurate prediction and acute pneumonia: 1, 2, 3, 4
    • accurate prediction and acute pneumonia respiratory distress: 1
    • accurate prediction and acute respiratory distress: 1, 2, 3, 4
    • active comparator and acute pneumonia: 1